EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Entrada Therapeutics's enterprise value is $-12.8 Mil.
Entrada Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $7.9 Mil. Therefore, Entrada Therapeutics's EV-to-EBITDA for today is -1.62.
The historical rank and industry rank for Entrada Therapeutics's EV-to-EBITDA or its related term are showing as below:
TRDA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -817.95 Med: 0.98 Max: 10.68
Current: -1.62
During the past 6 years, the highest EV-to-EBITDA of Entrada Therapeutics was 10.68. The lowest was -817.95. And the median was 0.98.
TRDA's EV-to-EBITDA is ranked better than 98.99% of 497
companies
in the Biotechnology industry
Industry Median: 7.69
vs TRDA: -1.62
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Entrada Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Entrada Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Entrada Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Entrada Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entrada Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entrada Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Entrada Therapeutics's EV-to-EBITDA falls into.
Entrada Therapeutics's current Enterprise Value is $-12.8 Mil.
Entrada Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Entrada Therapeutics's PE Ratio (TTM) for today is calculated as:
Entrada Therapeutics's share price for today is $7.69.
Entrada Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.810.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Entrada Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TRDA has been successfully added to your 